beby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as St Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, RECEIVEL on the date shown below. Date: IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Application of Dunn-Coleman et al. Group Art Unit: 1652 Serial No.: 10/027,000 Examiner: Rao, M. Filed: December 18, 2001 For: BGL4 Beta-Glucosidase and Nucleic Acids Encoding the Same **Supplemental Information Disclosure Statement** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56. This Information Disclosure Statement: (a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a). (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491. (c) as far as is known to the undersigned, is filed before the mailing date of a

first Office Action on the merits.

(d) is filed after the first Office Action and more than three months after the application-filing date-or-PCT-national-stage-date of-entry-filing-but,-as-far as is known to the undersigned, prior to the mailing date of either a final

	rejection or a notice of allowance, whichever occurs first, and is accompanied be either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitte herewith in duplicate.		
	allowar Transr No. 07 as spe consid	is filed after the mailing date of either a final rejection or a notice of nce, whichever occurred first, and is accompanied by authorization (in the nittal Letter submitted herewith in duplicate) to charge Deposit Account -1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification cified in 37 CFR §1.97(e), as checked below. This document is to be dered as a petition requesting consideration of the Supplemental nation Disclosure Statement.	
If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR			
§1.97(e) may need to be completed.] The undersigned certifies that:			
	counte	Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of his Information Disclosure Statement.	
	foreigr reasor	No item of information contained in this Information Disclosure Statement ted in a communication mailed from a foreign patent office in a counterpart a application or, to the knowledge of the undersigned after making hable inquiry, was known to any individual designated in 37 CFR §1.56(c) han three months prior to the filing of this Information Disclosure nent.	
A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for			
PCT/US02/34611, filed October 30, 2002 with attached patents and publications.			
⊠ ead	ch 🗌 r	none  only those listed below:	
A concise exp	lanatior	n of relevance of the items listed on PTO-1449 is: not given	
		given for each listed item	
		given for only non-English language listed item(s)	
		in the form of an English language copy of a Search Report from a patent office, issued in a counterpart application, which refers to the nt portions of the references.	

Serial No. 10/027,000

Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior

art "may be nothing more than identification of the particular figure or paragraph of the patent or

publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be

"material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any

patent, publication or other information referred to therein is "prior art" for this invention unless

specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall

not be construed to mean that a search has been made or that no other material information as

defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is

in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested

to consider the listed references.

Respectfully submitted,

Date: September 30, 2003

Victoria L. Boyd

Registration No. 43,510

ctoria L. Boyd

Genencor International, Inc.

925 Page Mill Road

Palo Alto, CA 94304-1013 Tel: 650 846-7615

Fax: 650 845-6504

## INFORMATION DISCLOSURE CITATION Serial No.: 10/021,000 Group: 1652 Date of this Submission: September 30, 2003 Attorney Docket No.: GC696 Serial No.: 10/027,000 Applicant: Nigel Dunn-& Filing Date: 12/18/01 Page 1 of Sub Isaa Supate **US PATENT DOCUMENTS** Filing Examiner's **Document** Class Initial Number Date Name **FOREIGN PATENT DOCUMENTS** Sub-**Translation** Examiner's Document Class Class Yes/No Number Date Country Initials OTHER DOCUMENTS Examiner's Author, Title, Date, Pertinent Pages, etc. Initials Belancic et al., β-Glucosidase from the Grape Native Yeast Debaryomyes vanrijiae: Purification, Characterization, and Its Effect on Monoterpene Content of a Muscat Grape Juice<sup>t</sup>, Journal of Agricultural and Food Chemistry, 51: 1453-1459, 2003. Saloheimo et al., Enzymatic Properties and Intracellular Localization of the Novel *Trichoderma reesei* β-Glucosidase BGLII (Cel1A), Applied and Environmental Microbiology, vol. 68, no. 9, pp. 4546-4553, 2002 Sawkar et al., Chemical chaperones increase the cellular activity of N370S β-glucosidase : A therapeutic strategy for Gaucher Disease, PNAS, vol. 99, no. 24, pp. 15428-154330, 2002 International Search Report for PCT/US02/34611

Examiner Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449